Inhibition of AMP deaminase (AMPD) holds the potential to elevate intracellular adenosine and AMP levels and, therefore, to augment adenosine signaling and activation of AMP-activated protein kinase (AMPK). To test the latter hypothesis, novel AMPD pan inhibitors were synthesized and explored using a panel of in vitro, ex vivo, and in vivo models focusing on confirming AMPD inhibitory potency and the potential of AMPD inhibition to improve glucose control in vivo. Repeated dosing of selected inhibitors did not improve glucose control in insulin-resistant or diabetic rodent disease models. Mice with genetic deletion of the muscle-specific isoform Ampd1 did not show any favorable metabolic phenotype despite being challenged with high-fat diet feeding. Therefore, these results do not support the development of AMPD inhibitors for the treatment of type 2 diabetes.
INTRODUCTION
AMP-metabolizing enzymes play an important role in maintaining adenine nucleotide homeostasis and cellular energy charge in situations of ATP depletion (Chen et al., 1996) . Adenylate kinase responds to transient drops in energy charge by catalyzing the conversion of two ADP to ATP and AMP, thereby counteracting the lowering of ATP concentration and simultaneously preventing ADP levels from rising. The AMP formed is, in turn, involved in the stimulation of catabolic pathways, many of which are coordinated by AMP-activated protein kinase (AMPK). AMP is then either deaminated via AMP deaminase (AMPD) to inosine monophosphate (IMP) or hydrolyzed to adenosine (via 5 0 -nucleotidase). Therefore, inhibition of both 5 0 -nucleotidase and AMPD has the potential to elevate AMP levels, cause downstream activation of AMPK, and boost catabolic pathways.
AMPK plays a central role in the regulation of cellular energy charge. It is activated by increases in AMP and ADP levels and, therefore, reacts to counteract energy deprivation (Oakhill et al., 2011 (Oakhill et al., , 2012 . AMPK phosphorylates and regulates several key metabolic enzymes to favor ATP production and, simultaneously, slow down anabolic pathways such as protein and fatty acid synthesis (for reviews, see Carling et al., 2012; Hardie et al., 2012b) . Not surprisingly, during recent years, several direct and indirect AMPK activators have been reported to act as metabolic modulators (Giordanetto and Karis, 2012; Zhou et al., 2009) . AMPK exists as variants of an a, b, g heterotrimer (a total of 2 a subunits, 2 b subunits, and 3 g subunits, giving rise to a total of 12 possible combinations) with different tissue distribution. Most tissues contain several AMPK variants, making it challenging to design organ-specific activators (see Viollet et al. (2010) and references therein). An alternative approach could be to modulate the activity of tissue-specific adenine nucleotide-metabolizing enzymes. Inhibition of these enzymes has the potential to elevate intracellular levels of AMP and, as a consequence, activate AMPK (Kulkarni et al., 2011; Plaideau et al., 2012) . However, data from multiple dosing studies using well tolerated AMPD or 5 0 -nucleotidase inhibitors in vivo have been lacking.
There are three different AMP deaminase, AMPD1, AMPD2, and AMPD3 isozymes with different tissue expression. In humans, AMPD1 is mainly found in skeletal muscle and, to some extent, in the heart. AMPD2 is expressed in the liver and brain, whereas both AMPD2 and AMPD3 are present in the heart, kidney, and spleen (Ogasawara et al., 1982) . Erythrocytes mainly express the isoform AMPD3 (Ogasawara et al., 1982) . Human AMPD1 deficiency leads to various muscle phenotypes, ranging from mild fatigue to myopathies with more marked differences observed when subjects with hetero-or homozygote mutations are compared with normal controls after acute and intense muscle exercise (Engel et al., 1964; Fishbein et al., 1978; Norman et al., 2001; Sabina et al., 1980) . Potent coformycin analog AMPD inhibitors have been described (Erion et al., 1999; Kasibhatla et al., 1998) , but with the liability of having limited cell permeability (Borkowski et al., 2008a (Borkowski et al., , 2008b , thereby restricting their use in oral multidosing studies. More recently, the widely used antidiabetic drug metformin was also demonstrated to act as an AMPD inhibitor, although at millimolar concentrations and in in vitro models (Ouyang et al., 2011) . Here we present a series of orally available AMPD pan inhibitors that potently inhibit AMPD activity in tissue homogenates as well as in intact cells. Examples from this series were also used for repeated dosing in obese, diabetic ob/ob mice as well as in insulin-resistant, diet-induced obese (DIO) mice at exposure levels above that required to inhibit the AMPD enzymes in intact cells as well as in tissue homogenates. No improvements in glucose control were observed in either of the disease models. Furthermore, no beneficial metabolic phenotype was observed in mice with genetic deletion of Ampd1 when fed a standard chow or when fed a high-fat diet. We also confirm that metformin indeed caused inhibition of the AMPD1 and AMPD2 isoforms, but the effect was rather weak and only significant at suprapharmacological concentrations of metformin.
RESULTS

HTS Screen and Hit Confirmation for Identification of AMPD1 Inhibitors
To identify AMPD1 inhibitors, an assay was developed suitable for 1,536-well high-throughput screening (HTS). The coupled assay allowed ammonia formed in the AMPD reaction to be used by glutamate dehydrogenase (GDH) to convert the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to nicotinamide adenine dinucleotide phosphate (NADP + ), which was monitored by a decrease in absorbance at 340 nm (Figure 1A) . A total of 884,000 compounds were analyzed. The assay quality was good to excellent, with Z' values (Zhang et al., 1999) ranging from 0.45-0.9 in the different runs ( Figure 1B ). The hit rate was around 1.9%, and all hits were selected for three-point concentration response (CR). A counterscreen based on adding ammonia instead of AMPD1 to mimic the second part of the reaction in Figure 1A was employed. This assay ensured the removal of compounds that interfered with the coupling reaction. The results showed that more than 95% of the tested compounds interfered with the second part of the reaction or the detection ( Figure 1C ). About 250 compounds of interest were selected for seven-point CR testing to investigate the correlation with the previously obtained three-point CR data. The correlation observed was considered to be good, but there were some deviations ( Figure 1D ). For all further work, seven-point CR data were used.
Properties and Optimization of Series 106
A racemate of compound 1 ( Figure 2B ) was confirmed as a low micromolar hit in the GDH-coupled seven-point CR assay described above. Being chemically stable, selective against closely related adenosine deaminase, and showing no similarity to other AMPD inhibitors (Bojack et al., 1999; Erion et al., 1994) , it offered the potential for structural variations to build up a structure-activity relationship (SAR) (Figure 2A ). The (R)-enantiomer of compound 1 was identified as the most potent isomer. The lead identification phase focused on optimizing potency, metabolic stability, and reactive metabolite formation (trapping studies and assessment of acyl glucuronide stability) by controlling and lowering lipophilicity in the design of subsequent compounds.
The zwitterionic character proved to be mandatory to retain potency. Isosteric replacements of the carboxylic acid motif with acidic H-bond donors resulted in a mild loss of inhibition, whereas replacement with non-H-bond donors caused a significant drop in potency. Small changes to the aryl acid motif, including substitution patterns and heterocyclic replacements, were generally well tolerated. A Caco-2 monolayer model was used to predict the fraction of the oral dose absorbed (f a ). Experiments were performed in an apical (pH 6.5) to basolateral (pH 7.4) direction. Despite the zwitterionic character of the compounds, the f a was predicted to be high. The less lipophilic compounds were more prone to efflux, which, in combination with glucuronidation in the gut, was, to some extent, limiting overall the bioavailability/absorption in rats (physiologically based pharmacokinetic simulations). However, the bioavailability was high enough to achieve adequate exposure in the in vivo studies. The common site of metabolism for the series of compounds was oxidation of the secondary benzylic carbon, forming a potentially reactive aldehyde that could be trapped by methoxyl amine.
A steep SAR was observed around the amine functionality. Switching to an amide was not tolerated, nor was the removal of the methyl substituent or additional substitution, which all lead to almost a complete loss of potency. However, any adducts to proteins in vivo were considered to carry a limited risk for adverse reactions because of the apparent reversibility of adduct formation. As a representative metabolite for the series, 6-(4-formylphenyl)nicotinic acid was tested and found to be inactive for potential mutagenicity in Salmonella typhimurium (Ames test) (Maron and Ames, 1983) .
Acyl glucuronide conjugation was a minor metabolic pathway. The reactivity of conjugates was assessed by estimation of the half-life for migration of glucuronic acid. The conjugates for all compounds tested were stable or moderately stable and consid- ered to be less reactive. The exchange of the naphthalene moiety, identified as a source of reactive metabolites trapped by glutathione, by the more polar quinoline resulted in an increased potency, thus improving ligand lipophilicity efficiency (LLE) by 2.5, and increasing metabolic stability. Physicochemical properties of the AMPD inhibitors are summarized in Table 1 . Table 2 shows potencies for the AMPD inhibitors as determined by concentration response testing using recombinant human and rodent enzymes as well as muscle and liver homogenates from Sprague Dawley rats and ob/ob mice. Apparent K m values for AMP in Sprague Dawley rat muscle and liver homogenates were found to be 1.2 and 5.5 mM, respectively. Corresponding values for recombinant rat AMPD1 and AMPD2 were 2.3 and 4.2 mM, respectively (data not shown). Figure 2C , top panel, shows the data for compound 2 and compound 3 ( Figure 2B ) when tested in the GDH-coupled AMPD assay using recombinant murine AMPD1 or muscle tissue homogenates from ob/ob mice. Compound 2 and compound 3 displayed rather similar half-maximal inhibitory concentration (IC 50 ) values for inhibition of the recombinant and native enzymes (4.5 versus 7 mM, respectively, for compound 2 and 0.024 versus 0.020 mM, respectively for compound 3) and, therefore, these enantiomers demonstrated a more than 200-fold separation in potency in both assays. A comparison for the AMPD2 isoform is shown in the bottom panel of Figure 2C , where the concentration response data for compound 2 and compound 3 in assays using either recombinant rat AMPD2 or rat liver tissue homogenates are given. Both compounds appear to be 2-to 3-fold more potent when tested on rat liver homogenates compared with recombinant rat AMPD2. A similar result was observed with compound 4, which also demonstrated significantly higher potencies in tissue homogenates versus the recombinant enzymes. This could possibly be due to recombinant enzyme concentrations being higher than native enzymes in the tissue homogenates (e.g., concentrations of mAMPD1 and rAMPD2 = 18 and 53 nM, respectively). If the active site concentration equals the enzyme concentration in these cases, this may result in an apparent lower potency because of compound depletion. Metformin has been reported to partially inhibit AMPD1 activity at millimolar concentrations (Ouyang et al., 2011) . Figure S1 (available online) shows the results from concentration response testing up to 20 mM metformin in the rat AMPD1 and AMPD2 assays. The only significant effect was observed at 20 mM metformin, where AMPD1 and AMPD2 were inhibited by 27% and 28%, respectively.
Concentration Response Data for Recombinant Enzymes and Tissue Homogenates
AMPD Inhibition in ATP-Depleted Primary Rat Hepatocytes
Compounds 2, 3, and 4 were tested for effects on nucleotide levels following the protocol described by Erion et al. (1999) using freshly prepared rat hepatocytes in suspension before and after ATP depletion by addition of 0.5 mg/ml fructose (2.8 mM). ATP reduction and IMP formation occurred instantly and already reached a maximum after 5 min of fructose exposure ( Figure 3A) . IMP levels increased from below the detection limit to 4.5% of total nucleotides concomitant with fructose-induced ATP depletion. Figure 3B shows the concentration response for inhibition of IMP formation by compound 3 and compound 4 with an estimated IC 50 < 0.5 mM for both compounds, which is in agreement with the potencies seen in the rat liver homogenate assay. As a result of inhibiting AMPD activity, the already high AMP levels because of fructose phosphorylation became further elevated, as seen in Figure 3C . Although both compound 3 and compound 4 robustly inhibited IMP formation along with accompanying elevations in AMP, compound 3 appeared to be slightly more potent, despite opposite ranking in the liver homogenate assay. The inactive enantiomer, compound 2, had no significant effects on nucleotide levels. Exposure to compounds 3 and 4 also decreased levels of the downstream nucleosides, inosine and hypoxanthine, as a consequence of AMPD inhibition. However, variation in the adenosine levels was too large to see the expected rise in adenosine. None of the tested compounds had any effects on adenine nucleotide levels prior to increasing flux through AMPD following fructose-induced ATP depletion (data not shown).
Repeated Dosing of DIO and ob/ob Mice with AMPD Inhibitors Two repeated dosing studies in disease models of insulin resistance (DIO mice, compounds 2 and 3) and diabetes (ob/ob mice, compound 3) were performed. Table 3 summarizes the data from the 2-week repeated dosing study in DIO mice with vehicle and with compound 2 and compound 3, both dosed orally at 300 mmol/kg twice daily (b.i.d.). The plasma concentration achieved for compound 2 and compound 3 (Table 3) corresponded to an estimated average concentration unbound in plasma of 0.2-fold or 50-fold above that of the mouse AMPD1 IC 50 (Table 2) , respectively, over the 2-week treatment period. Similar exposure levels for compound 3 were shown to cause AMPD inhibition in rat isolated muscle strips (see accompanying article by Plaideau et al., 2014) , therefore supporting the compound's ability to penetrate muscle tissue and into myotubes. Body weight was reduced in all three groups during the 2-week dosing period, but the body weight reduction was not significantly different between the vehicle-and compoundtreated groups (Table 3) . Following 2 weeks of repeated dosing, an oral glucose tolerance test (OGTT) was performed. Basal glucose and insulin levels were increased in the compound 3-treated group at the start of the OGTT. Calculations of homeostatic model assessment (HOMA) insulin resistance index (glucose (millimolar) 3 insulin (pg/ml)) from the basal glucose and insulin levels suggested an impairment in glucose control, but the incremental area under the curve (AUC) for glucose and insulin levels was not significantly different between any of the cohorts (Table 3) . Dosing of compound 3 (300 mmol/kg/day, b.i.d.) to obese, diabetic ob/ob mice for 1 week resulted in a reduction in body weight gain compared with vehicle-treated mice (Table S1 ). Body weight gain decreased despite no difference in cumulative food intake over the whole dosing period (vehicle control, 5.3 g/mouse/day; compound 3, 5.1 g/mouse/day, respectively). Plasma glucose and insulin levels after 3 hr of fasting were (Table S1 ) and were not significantly altered by compound 3 treatment. The HOMA insulin resistance index was not significantly different between the vehicle-and compound 3-treated groups. Lack of treatment-induced improvement in average diurnal glucose control was supported by similar fructosamine levels in the compound 3-treated group compared with the vehicle control group (Table S1 ). Compound 3 treatment did not affect plasma levels of triglycerides (TGs) or free fatty acids. Based on the plasma levels shown in Table S1 , the estimated concentration of compound 3 unbound in plasma is 80-fold higher than the IC 50 of mouse AMPD1 (Table 2) .
Ampd1-Deficient Mice
Ampd1-deficient animals (Ampd1 knockout [KO]) were generated by a targeted deletion at the Ampd1 locus ( Figure S2A ) and positive embryonic stem (ES) cell clones were identified by Southern blot analysis ( Figure S2B ). Ampd1 deficiency was confirmed by RT-PCR analyses of RNA derived from skeletal muscle from wild-type, heterozygous, and homozygous Ampd1 mutant mice ( Figure S3C ). As expected, no expression of Ampd1 was observed in the Ampd1 KO mice ( Figure S3C ). The western blot analysis presented in the accompanying paper by Plaideau et al. (2014) confirmed that no AMPD1 protein or additional downstream translational products were present in extensor digitorum longus (EDL) and soleus muscle from the Ampd1 KO mice. Fainter, 50,000-Mr bands were observed in immunoblots of both EDL and soleus muscle from wild-type mice. However, these bands were also present in the same blots for EDL and soleus muscle from Ampd1 KO mice. One would not expect to see these bands in both wild-type and Ampd1 KO muscles in the event of odd splicing from exons 1-6 to exon 14 in the knockout. AMPD activity was also measured in skeletal muscle homogenates from Ampd1 KO (n = 8) and wild-type (n = 8) mice using the GDH-coupled assay as described above.
Muscles from Ampd1 KO mice had undetectable AMPD activity, The values are mean ± SD. #, below the detection limit of the system; *p < 0.03 compared with the DMSO controls in a two-tailed Student's t test.
whereas the wild-type muscle homogenates had expected levels of compound 3-sensitive deaminase activity ( Figure S2C ).
Intercrossing of male and female mice heterozygous for the Ampd1 mutation resulted in offspring of normal litter sizes. Of the male offspring, 20% were homozygous, 51% were heterozygous, and 29% were wild-type mice. The Ampd1 KO mice were healthy and appeared normal, displaying no obvious adverse phenotype over the course of the study. No significant differences in body weight gain were observed between the cohorts of Ampd1 KO and wild-type mice fed the chow diet or those on a high-fat diet (HFD) ( Figure 4A ). As expected, the wild-type mice on an HFD displayed a greater body weight gain compared with those fed the chow diet so that, at study termination, the former were more than 50% heavier (p < 0.001) ( Table S2 ). The chow-fed Ampd1 KO mice had increased body length at 30 weeks of age (but not at earlier time points) compared with the chow-fed, wild-type control animals (wild-type, 10.5 ± 0.0 cm; Ampd1 KO mice, 10.7 ± 0.1 cm; p < 0.05). Body length did not differ significantly between the cohorts fed an HFD at any time point assessed (data not shown). Assessment of body composition was performed in 17-and 30-week-old animals and revealed no significant difference in any measured parameter, including absolute and relative lean body mass, body fat mass, bone mineral content, or bone mineral density, between Ampd1 KO and wild-type mice, neither when on chow or an HFD (data not shown). The mice were analyzed with respect to energy intake, fecal energy output, energy expenditure, respiratory exchange ratio, core body temperature, and locomotor activity. The Ampd1 KO mice displayed no significant alterations in any of these parameters when compared with the wild-type controls when fed chow or an HFD (energy expenditure data (Oxymax) are shown in Figure S3 ). In addition, the Ampd1 KO mice displayed no sign of depression or anxiety when compared with the wild-type mice, irrespective of diet. No significant differences were observed in an open field locomotor activity test between the chow-fed Ampd1 KO and wild-type mice. However, the Ampd1 KO mice on an HFD had significantly increased horizontal and total activity, increased rearing time, and less time spent in corners in the open field box compared with the HFD-fed wild-type mice.
Glucose tolerance was assessed by an OGTT. There was no significant difference in fasting blood glucose, fasting insulin levels, or HOMA index between Ampd1 KO and wild-type mice on a chow diet or between Ampd1 KO and wild-type mice (A) Body weight gain from 4-14 weeks of age in standard chow-fed (SCD) wildtype mice (n = 8, filled circles), Ampd1 KO mice (n = 8, filled circles), HFD-fed wild-type mice (n = 8, filled squares), and Ampd1 KO mice (n = 8, open squares). Statistical analysis was performed using repeated Student's t test.
(B and C) Oral glucose tolerance test in chow-fed wild-type mice (n = 7, filled circles), Ampd1 KO mice (n = 7, open circles), HFD-fed wild-type mice (n = 7, filled squares), and Ampd1 KO mice (n = 7, open squares). The results are presented as mean ± SEM. Statistical analysis of AUC values was performed using Student's t test.
on an HFD ( Figure 4B ). Also, no significant differences were observed in terms of blood glucose or insulin responses (AUC) between Ampd1 KO and wild-type mice on either diet (Figure 4B ). There was a slight trend toward increased insulin levels (AUC, p = 0.083) and HOMA index (p = 0.17) in chow-fed Ampd1 KO mice compared with wild-type mice. At sacrifice, no significant differences were observed in body weight or in the absolute or relative (to body weight) weight of liver and heart between Ampd1 KO and wild-type mice fed a chow diet. The Ampd1 KO mice fed an HFD displayed a higher relative weight of the heart, whereas the body and liver weights were unaltered compared with HFD-fed wild-type mice. Mice on an HFD displayed increased body weight and liver weight, regardless of genotype, compared with chow-fed mice, as expected (Table  S2 ). Table S2 also shows the results of the biochemical analysis of plasma samples collected at termination. Insulin levels were increased significantly in chow-fed Ampd1 KO mice compared with chow fed wild-type mice (Table S2 ). There was a slight trend toward increased insulin levels in HFD-fed Ampd1 KO mice compared with the HFD-fed wild-type mice (2.2-fold increase, p = 0.08). Glucose levels were not different in the wild-type or Ampd1 KO mice on either diet. No differences were observed in any of the other plasma parameters assessed between Ampd1 KO and wild-type mice on any of the diets (Table S2) .
DISCUSSION
Chronic nutrient overload in combination with a sedentary lifestyle is known to contribute to metabolic inflexibility and insulin resistance in peripheral tissues. Long-term energy excess is postulated to cause oxidative stress and modulate pathways regulated by cellular energy sensors such as AMPK. Examples of AMPK-regulated pathways sensitive to energy status are cellular recycling mechanisms including autophagy, mitophagy, and antioxidant defense enzymes (Egan et al., 2011; Greer et al., 2007; Kim et al., 2011; Lee et al., 2010; Shang et al., 2011; Zhao and Klionsky, 2011) . Drug treatments mimicking feeding-fasting cycles in terms of intracellular energy sensing (e.g., AMPK activation) therefore have the potential to attenuate some of the negative effects caused by continuous oxidative stress and subsequent cellular damage. Difficulties in identifying tissue-selective and safe direct activators of AMPK have sparked an interest in finding alternative, indirect mechanisms to increase AMPK activity. Metformin and thiazolidineiones, along with other weak metabolic inhibitors, have been demonstrated to increase intracellular AMP:ATP ratios with downstream AMPK activation as part of their biological effects (reviewed in Hardie et al., 2012a; Zhang et al., 2009) . In this investigation, we attempted to inhibit the breakdown of AMP by AMPD rather than to increase AMP by restricting mitochondrial ATP synthesis. HTS of an AstraZeneca R&D compound collection using recombinant human AMPD1 yielded a series of inhibitors that, after further optimization, generated compounds suitable for in vivo testing (Figure 2 ). Chiral separation of an AMPD inhibitor racemate resulted in two pure enantiomers, compound 2 and compound 3, with a large separation in potency, making them suitable for biological concept testing and target validation. A panel of in vitro and ex vivo assays confirmed the potency of the tested compounds, and they were dosed in vivo to give exposure levels several-fold above the determined IC 50 values for AMPD1.
Critical for AMPD inhibitor-induced AMP accumulation is a high enough basal flux through AMPD to IMP. Data from human subjects with a defect in AMPD1 show that there is a trend toward an elevation of both AMP and ADP in resting muscle, but it is not clear whether this relatively small increase would translate into any significant AMPK activation (Norman et al., 1995) . However, individuals with AMPD1 deficiency also display a faster loss of muscle power during sprint exercise compared with normal subjects (Fischer et al., 2007) , an observation that is not in line with the postulated exercise mimetic effects described for AMPK activators (Narkar et al., 2008) . Therefore, previously reported human data do not give a clear answer to whether inhibition of AMPD in a resting muscle would result in any physiologically relevant elevation of AMPK activity.
Compounds 3 and 4 both inhibited IMP formation induced by ATP depletion and simultaneously increased AMP levels in hepatocytes. In addition, AMPD activity in homogenates of mouse and rat muscle and liver was potently blocked by the compounds, confirming their ability to inhibit the enzymes in the context of endogenous tissue complexity. Our investigation also included a multiple dosing study using ob/ob mice as a model of obesity and diabetes. This model has been proven sensitive and predictive in terms of insulin sensitization by other well characterized antidiabetics, such as the peroxisome proliferatoractivated receptor agonists (Ljung et al., 2002) . Although our multiple dosing protocol in mice resulted in exposure levels high enough to ensure almost full 24-hr coverage regarding inhibition of AMPDs, we were unable to detect any robust effects on metabolism in either ob/ob or DIO mice. In the DIO mice, fasting glucose and insulin levels were slightly elevated following 2 weeks of repeated dosing with AMPD inhibitor compound 3, but no difference was seen in either the glucose or insulin AUC following the OGTT. In the Ampd1-deficient mice, insulin levels were increased in the chow-fed group but not in the HFD-fed group compared with wild-type mice. The Ampd1-deficient mice displayed no other alteration in any of the metabolic parameters assessed, including body weight; body fat mass; and energy intake, uptake, or expenditure, either when fed a normal chow diet or when on an HFD. The increased insulin levels seen in the Ampd1 KO mice and after AMPD inhibition in DIO mice suggest an association between the loss of Ampd1 gene function and increased plasma insulin levels. Goodarzi and colleagues have shown, in Mexican Americans, that different human haplotypes for AMDP1 result in either increased or decreased insulin clearance but with no effect on fasting insulin levels or glucose infusion rate during clamp studies (Goodarzi et al., 2005) . Other human population studies have, however, demonstrated no or, instead, protective effects in terms of prevalence of type 2 diabetes in subjects carrying the inactivating AMPD1 C34T polymorphism, making interpretations difficult (de Groote et al., 2006; Safranow et al., 2009) .
The widely used antidiabetic drug metformin was also tested for inhibitory effects on rat recombinant AMPD1 and AMPD2. As seen in Figure S1 , 20 mM metformin was required to cause any significant inhibition of enzyme activity. Pharmacological doses of metformin generally result in peak exposure levels below 4 mg/l ($30 mM) (Klepser and Kelly, 1997), requiring more than 500-fold accumulation in, for example, hepatocytes to reach concentrations high enough to inhibit AMPD activity. Although metformin is known to be a substrate for transporters such as the organic cation transporter 1 (Oct1) in hepatocytes, the reported level of metformin accumulation because of active transport via Oct1 in mouse liver is only 4-to 30-fold higher (Shu et al., 2007; Wang et al., 2002) . Metformin is, therefore, not likely to reach the intracellular concentrations required to inhibit AMPD, at least not in hepatocytes.
In summary, we conclude that basal AMPD flux in liver and muscle is nondetectable to low at energy excess, a state represented in the chronic mouse disease models and, most likely, in the majority of the obese and type 2 diabetes patient population. In rat epitrochlearis muscle subjected to mild contractions in vitro, AMPK activation could be potentiated by AMPD inhibitors, but this did not lead to an enhancement of glucose uptake (see the accompanying paper by Plaideau et al., 2014) . Therefore, the concept of inhibiting AMPD as a means of elevating intracellular AMP levels and inducing AMPK activity is not supported by this study and is not likely to be a viable approach for improving insulin sensitivity and treating type 2 diabetes in patients. However, the AMPD inhibitors presented here will hopefully be useful tools for explorative work in different biological contexts, such as disease states with confirmed energy depletion and adenine nucleotide breakdown, but may also serve as starting points in the search for new and more efficient herbicides (Bojack et al., 2001; Lindell et al., 1999 Lindell et al., , 2010 .
SIGNIFICANCE
We identified potent small molecule inhibitors of human and rodent AMPDs. Chiral separation of an inhibitor racemate gave rise to a pair of enantiomers, compound 2 and compound 3, with a wide separation in potency for inhibiting the AMPDs, thus providing an attractive pair of tool compounds for validation and mechanistic studies. The discovered chemical series represented by compound 3 and compound 4 in this study was shown to be bioavailable and cell-permeable, with potencies translating from recombinant enzyme assays to inhibition of native enzyme activity in tissue extracts. Although it is well established that treatments lowering cellular energy status will cause changes in adenine nucleotide levels and, subsequently, activate AMPK, it has not been elucidated whether blockade of AMP breakdown via the AMPDs under normophysiological conditions would mimic a drop in energy charge. In this study, we applied both pharmacological and genetic inactivation of AMPD to test this hypothesis. Our investigation demonstrated the limited impact of AMPD inhibition on IMP and AMP levels under conditions of excess energy. Consequently, none of the postulated antidiabetic effects because of AMPK activation could be observed after multiple dosing of the inhibitors to DIO or ob/ob mice or in mice with a deletion of the gene encoding the muscle AMPD isoenzyme. However, the described AMPD inhibitors would be important tools for further investigating AMPD function in disease states with confirmed energy depletion and adenine nucleotide breakdown.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant AMPD Enzymes DNA fragments encoding full-length human AMPD1 (NCBI Reference Sequence (RefSeq) database ID code NM_00036), rat AMPD1 (ID code NM_138876), rat AMPD2 (ID code NM_001101681), and rat AMPD3 (ID code NM_031544) were cloned into the baculovirus expression vector pFastBac-1 (Invitrogen) between restriction sites BamHI and XhoI, respectively. Human AMPD2 (NCBI RefSeq database ID code NM_004037) and AMPD3 (ID code NM_001172430) were cloned into the vector pFastBac-1 between restriction sites BamHI and XbaI. Correct DNA sequences were confirmed by DNA sequencing. High-titer virus stocks were prepared in Sf9 (Spodoptera frugiperda) insect cells according to the manufacturer's protocol (Invitrogen). Recombinant AMPD1, AMPD2, and AMPD3 enzymes were expressed in Sf21 (Spodoptera frugiperda) cells incubated with Sf-900 II SFM medium (Invitrogen) for 72 hr in a 1 l shaking flask and purified from extracts prepared in buffer containing 10 mM potassium phosphate (pH 6.6), 500 mM KCl, 0.1% (v/v) mercaptoethanol, 5 mg/ml leupeptin, and 10 mM E-64 by column chromatography on Whatman P11 cellulose phosphate, as described previously (Haas and Sabina, 2003) . Protein identities were confirmed by MALDI-TOF/TOF mass spectrometry.
AMPD High-Throughput Screening Assays GDH was purchased from Roche, and all other material was purchased from Sigma, unless stated otherwise. Microtiter plates were from Greiner. AMPD1 was added to buffer A (50 mM HEPES, 150 mM KCl, 5 mM MgCl 2 , and 0.5 mM glutathione [pH 7.4]) to a concentration of 10 nM. A substrate mix consisting of 2 mM NADPH, 6 mM a-ketoglutarate, 8 mM AMP, and 15 U GDH was prepared in buffer A.
Assay ready plates were prepared by adding 50 nl of compounds to 1,536-well clear plates. HTS was performed using a bench cell robotic system equipped with a Flexdrop dispenser, V-spin centrifuge, and Pherastar detector. Substrate mix (4 ml) was added to the plate, followed by centrifugation and incubation for 1 hr. Detection was by absorbance at 340 nm following the conversion of NADPH to NADP + .
Three-point dose-response curves using compound concentrations of 25, 2.5, and 0.25 mM were used to identify statistically relevant hits. To remove false positives as well as nonspecific promiscuous binders, a counterscreen was performed where AMPD was replaced by NH 4 + . Positive hits in the counterscreen were removed. Further analysis of selected compounds was performed using a seven-point concentration response, with the highest concentration of 62 mM followed by 3-fold dilutions. Selected compounds were also analyzed in the counterscreen.
Synthesis of AMPD Inhibitors
The designed inhibitors were prepared from commercially available 4-bromoarylcarboxylic acid and 4-formylphenylboronic acid by Suzuki coupling, followed by reductive amination with racemic 1-(isoquinolin-8-yl)ethanamine. The enantiomers were separated by preparative chiral high-performance liquid chromatography (HPLC) (see Supplemental Experimental Procedures for more detail).
Detection of AMPD Enzymatic Activity
Recombinant AMPD enzyme activity assays were performed in a 384-well format using the same conditions as described above, except the assay volume was 80 ml and the AMP concentration for the AMPD2 assay was 8 mM. Different AMPD enzyme concentrations were used to have linear reactions: hAMPD1 (4 nM), hAMPD2 (38 nM), hAMPD3 (1 nM), rAMPD1 (116 nM), rAMPD2 (53 nM), rAMPD3 (31 nM), and mAMPD1 (816 nM). All experimental procedures involving animals were approved by the Local Ethics Review Committee on Animal Experiments (Gö teborg region). Tissues for measurement of AMPD activity were collected from Inactin-anesthetized (thiobutabarbital, 120 mg/kg intraperitoneally) male rats (Sprague Dawley), or isoflurane inhalation-anesthetized male ob/ob mice (see below), or Ampd1 KO and littermate wild-type mice. The animals were euthanized, and freeze-clamped wing tongs cooled in liquid N 2 were used to collect tissues. For AMPD assays, tissues were powdered under liquid nitrogen and homogenized (Ultra-Turax for 2 3 20 s) in 10 volumes (volume/wet weight) of buffer containing 50 mM HEPES, 150 mM KCl, 5 mM MgCl 2 , and 0.5 mM glutathione (pH 7.4), supplemented with 1 tablet of Complete protease inhibitor cocktail/ 10 ml (Roche). The crude homogenates were centrifuged at 800 3 g for 5 min at 4 C. The supernatants were then further homogenized in a glass/ Teflon homogenizer (15 strikes) on ice and finally cleared by centrifugation at 20,800 3 g (4 C) for 10 min for storage at À190 C until further use. AMPD activity was measured using a GDH-coupled 96-well assay with detection of NADPH oxidation as described above. Extracts (5.5 and 76 mg) of muscle or liver homogenate protein were added to each well containing 50 mM HEPES, 150 mM KCl, 5 mM MgCl 2 , and 0.5 mM glutathione (pH 7.4) before starting the reaction by adding substrate as described above but with final concentrations of 5 and 10 mM AMP for the muscle and liver assays, respectively. Inhibition values of 0% and 100% correspond to activities measured in separate control wells in the presence of 1% DMSO or 100 mM compound 3, respectively. Assays were performed in a Corning black flat 96-well plate at room temperature using an Infinite M200 plate reader (Tecan) set with a kinetic cycle taking readings at 1-min intervals after 5 s of orbital shaking and with excitation and emission wavelengths of 338 and 445 nm, respectively (top reading). The percentage of inhibition for the compounds was calculated in the linear range prior to depletion of substrate in the 0% control (DMSO). Protein concentration was determined using the Pierce bicinchonimic acid protein assay kit with bovine serum albumin as a standard.
Isolation of Rat Hepatocytes
Hepatocytes were isolated from female Sprague-Dawley rats. The rats were anesthetized with sodium pentobarbital ($75 mg/kg). A cannula was inserted in the portal vein, and the inferior caval vein was opened. The liver was perfused (25 ml/minute) in situ via the portal vein with Ca 2+ -free Hank's balanced salt solution (HBSS) (pH 7.4) with 0.6 mM EGTA, 10 mM NaHCO 2 , and 20 mM HEPES. After 10 min of perfusion, the medium was changed to HBSS containing 10 mM NaHCO 2 , 20 mM HEPES, 5 mM CaCl 2 , and 0.13 U/ml of Collagenase A. Perfusion continued for an additional 7 min before the liver was removed and placed in a Petri dish with cold Williams medium E supplemented with 5% (v/v) fetal bovine serum (FBS) and 500 U/ml of penicillin and streptomycin. The liver capsula was gently broken with a sharp instrument to release cells into the medium. To remove residual tissue, the cell suspension was filtered through a 250 mm nylon mesh and then through a 100 mm mesh filter. The cells were divided into two 50 ml Falcon tubes, and cold Williams medium E containing 5% FBS and 500 U/ml of penicillin and streptomycin was added up to 50 ml, followed by centrifugation (70 3 g for 3 min) at 4 C.
The cells were resuspended in cold Williams medium E supplemented with 5% FBS and 500 U /ml of penicillin and streptomycin, followed by centrifugation (see above). Cell washing was repeated once before resuspending cells in 20 ml Williams medium E supplemented with 5% (v/v) FBS, 500 U/ml of penicillin and streptomycin, 100 nM Selenit, 0.28 mM vitamin C, 1 nM dexamethasone, and 3.6 nM insulin. Cells were counted in a FastRead 102 counting slide and seeded at a density of 500,000 cells/well in Collagen 1-coated, 12-well plates. After 4 hr of incubation at 37 C, the medium was removed, and new
Williams medium E supplemented with 500 U/ml of penicillin and streptomycin, 100 nM Selenit, 0.28 mM vitamin C, 1 nM dexamethasone, and 3.6 nM insulin was added for serum starvation overnight.
Cell-Based AMPD Assay
Freshly isolated hepatocytes (4.8 3 10 6 cells/ml) from female SpragueDawley rats were incubated at 37 C in assay medium consisting of HEPES-buffered minimum essential medium (25 mM, Gibco, catalog no. 21011-044) supplemented with 5 mM sodium pyruvate (Invitrogen, catalog no.11360-039) and 1 mg/ml nonessential amino acids (Invitrogen, catalog no. 11140). The cells were subjected to gentle swirling and incubated with 0.5 mg/ml (2.8 mM) fructose and 0.1% (v/v) DMSO or the indicated concentrations of the AMPD inhibitors. Samples were withdrawn and snap-frozen before and after 5 min of fructose treatment. Extracts were prepared for nucleotide measurement using a liquid chromatography (LC) with UV detection system as described below.
Extraction and Analysis of Nucleotides by HPLC-UV Detection
Extracts from cells in 12-well plates were prepared by the addition of 500 ml of 0.05 M perchloric acid in ice-cold 40% CH 3 OH by mild vortexing for 15 min.
The cell-free extracts were then transferred to 96-well glass vials, neutralized with 60 ml 0.44 M (NH 4 ) 2 HPO 4 in water, and evaporated to dryness in HPLC glass vials at 50 C under a stream of N 2 . The analytes were dissolved in 100 ml water, of which 10 ml was injected onto the HPLC system. Separation was achieved on a Waters Atlantis T3 column (100 Å , 3 mm, 3 3 100 mm, catalog no. 186003722) over 20 min using a binary solvent system and the following gradient program: 0% B from 0-2 min, to 15% B at 10 min, and to 50% B at 20 min. A washout step with 100% B for 5 min and an equilibration step at 0% B for 5 min were performed prior to the next injection. The mobile phases were 0.1 M (NH 4 ) 2 HPO 4 buffer (pH 6) in water (A) or 50% CH 3 OH (B). Nucleotides in sample extracts and calibration samples were then determined quantitatively by UV diode array detection at 254 nM. Peak purity testing was based on absorbance at 248 nm and 262 nm for adenine nucleotides and nucleosides, respectively. Calibration and quality control samples were prepared in 1% (w/v) PBS. The detection limit for IMP was about 1 pmol injected. The LC-UV system was a Dionex P580 pump, a Biotech Model 2003 degasser, CTC Analytics PAL 96-well autosampler (held at 15 C), and a Gynkotek UVD 320S DAD. LC pump pistons were rinsed continuously using circulating 20% methanol to avoid the formation of crystals from the buffers. Table 2 for mouse in vitro potencies). Body weight was measured repeatedly throughout the study. After 2 weeks of treatment, an OGTT was performed on 4 hr fasted mice. Starting at 8 am, the mice were fasted in clean cages for 4 hr. A sample was collected for analysis of glucose and insulin, followed by oral gavage with 2 g/kg D-glucose. Repeated blood samples were taken via the tail vein 15, 30, 60, 90, and 120 min after the glucose challenge. At each time point, one blood drop was used for glucose measurement (AccuChek Abbott) and 2 3 3 ml blood was collected for insulin measurements (Ultra Sensitive Insulin ELISA kit, Chrystal Chem with addition of heparin [20 ml. 1 mg/ml] to the sample diluent bottle). The following day, the animals were sacrificed, and plasma was collected 3 hr after the final dose for measurement of compound concentrations.
Repeated Dosing in DIO Mice
Biochemical Analysis of Plasma
Plasma insulin was determined with a radioimmunoassay (RIA) (mouse Insulin RIA kit, Millipore). Colorimetric kit methods were used for the measurement of plasma glucose and lactate (Horiba ABX), triglycerides (Roche Diagnostics), free fatty acids (Wako Chemicals), D-3-hydroxybutyrate, and fructosamine (Randox). Liver triglyceride content was determined after tissue homogenization in isopropanol. Triglycerides in the supernatant were measured using an enzymatic colorimetric method (Horiba ABX). For determining compound concentrations, plasma samples were precipitated with acetonitrile. After centrifugation, the supernatant was diluted with 0.2% formic acid. Analysis was performed on a short reversed-phase HPLC column with rapid gradient elution and mass spectrometry (MS)/MS detection using a triple quadruple instrument (Waters Quattro Ultima) with electrospray ionization and selected reaction monitoring acquisition.
Generation of Ampd1-Deficient Mice A Lox-P strategy was used to target the Ampd1 locus to generate Ampd1-deficient mice. A 14.5 kb fragment of a C57BL/6 mouse genomic subclone was used as targeting vector, containing a floxed neomycin phosphotransferase selection marker cassette after the coding sequence in the UTR and a single Lox-P site inserted in intron 6 of the Ampd1 locus (illustrated schematically in Figure S1A ). The targeting vector was linearized by using SacII and electroporated into C57BL/6 mouse ES cells (derived from C57/J, Genome Systems) which were then grown in medium containing G-418 (300 mg/ml). The Ampd1-deficient mouse line was thus established on a pure C57BL/6 genetic background. The candidate ES cell clones were screened by PCR over the short arm homology of the construct, and the gene targeting event was further confirmed by Southern blot analyses using BamHI restriction enzymes (Figure S1B) . One clone was expanded and injected into BALB/c blastocysts to generate chimeric mice. Chimeric offspring was bred with C57BL/6N mice (Charles River Laboratories) to produce black-coated offspring. The following primers were used to identify offspring with the targeted allele: forward neospecific primer (F) 5 0 -TCCTGCCGAGAAAGTATCCATCATÀ3 0 together with a reverse primer within the short arm homology (R1): 5 0 -CTCGAAGGCTTGCG CTACCACTAAÀ3 0 . Heterozygous mice carrying Lox-P DNA sites were bred with ROSA26Cre mice (Soriano, 1999 ) that had been backcrossed more than 20 generations with C57BL/6N mice (Charles River) to generate heterozygous Ampd1-deficient mice. The mice were identified using the genotyping primers 5 0 -TTGAAGCATCTGAAAGTGGAGGGAÀ3 0 , 5 0 -CATAAGAGGGAGTG GTTGCAGGAA-3 0 , and 5 0 -TGGACCATCACGATTCATTTGTTAÀ3 0 and resulted in 838 bp products for the recombined allele and 254 bp products for the wild-type allele. Heterozygous Ampd1-deficient mice were intercrossed to generate homozygous Ampd1-deficient animals that proved to be viable. To verify the Ampd1-null mutation, total RNA was prepared from skeletal muscle of 5-week-old homozygous, heterozygous, and wild-type littermates using the RNA STAT-60 kit according to the manufacturer's instructions (Tel-Test). cDNA was synthesized using Superscript TM II RNase H -reverse transcriptase and random hexamer primers (Life Technologies). RT-PCR was performed using the primers 5 0 -ATCTTACCATATTGACGCCGACAG-3 0 (forward) and Ex 5 0 -TGCACCCACCTCCTTGATGATAGT-3 0 (reverse) (Figure S1C ) to show that exons 7-13 were deleted in the Ampd1-deficient mice. The Ampd1 heterozygous mouse colony was expanded by breeding with C57BL/6N mice (Charles River) and heterozygous intercrossing was performed to produce Ampd1 homozygous experimental and wild-type littermate control cohorts having a pure C57BL/6N genetic background. Male Ampd1-deficient and control mice were housed individually in a temperature-controlled room (22 C) with a 12 hr light-dark cycle. They had free access to normal chow diet (R36, Lactamin AB) and water. The R36 chow diet contains (energy %) 22.9% protein, 67.1% carbohydrate, and 9.6% fat with a total energy content of 3.08 kcal/g. For the HFD experiments, the HFD used was D12492 (Research Diets) containing (energy %) 60% fat, 20% carbohydrates, and 20% protein with a total energy content of 5.20 kcal/g.
In Vivo Phenotypic Screening
The Ampd1-deficient (Ampd1 KO) mice and control cohorts (wild-type) were studied in a series of tests from 4-31 weeks of age. Body weights were recorded weekly from 4-14 weeks of age and then again at study termination. At 8 weeks of age, the mouse cohorts were subdivided into two groups, and one cohort of Ampd1 KO mice (n = 8) and one cohort of wild-type mice (n = 8) were switched to the HFD, whereas a second cohort of Ampd1 KO mice (n = 8) and wild-type mice (n = 8) remained on the chow diet. The HFD was provided over a 23-week period. An OGTT was performed on 19-to 20-weeks-old mice (12 weeks after HFD introduction) as described previously (Bjursell et al., 2007) . Assessment of behavior was performed on 16-to 18-week-old animals as described previously (Gerdin et al., 2006) . All mice were terminated at 31 weeks of age, 23 weeks after the introduction of the HFD for the intended groups. The mice were fasted for 3 hr and then anaesthetized by isoflurane inhalation. Blood was collected in EDTA-coated tubes by cardiac puncture. Blood plasma was separated by centrifugation (2500 rpm, 10 min, 4 C) and snap-frozen in liquid N 2 . The heart and liver were blotted and weighed. For more details, see Supplemental Experimental Procedures.
Statistical Analyses
The results are presented as mean ± SEM. For the compound repeated dosing studies in DIO and ob/ob mice, comparisons were made between test substance-treated mice and the vehicle group using unpaired Student's t test. A value of p < 0.05 was considered statistically significant. For the wild-type versus Ampd1 KO studies, statistical calculations for pairwise single parameters measured at one time point were performed using Student's t test. Statistical calculations of parameters measured over time were performed by two-way ANOVA. p < 0.05 between the groups was considered to be statistically significant. Preparative HPLC was conducted on a Gilson purification system using an Xbridge Prep C18
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(10 μm OBD, 250 x 50 mm) column. The mobile phase used was varying gradients of CH 3 CN and 0.2% NH 3 buffer at a flow rate of 100 ml/min.
All tested compounds were determined to be >95% pure using the analytical method (a) or (b) described above based on the peak area percentage. 
6-(4-Formylphenyl)nicotinic acid
Four microwave vials were each loaded under argon with 4-formylphenylboronic acid (1.575 g, 10.5 mmol), 6-bromonicotinic acid (2.12 g, 10.5 mmol), ethanol (9 ml), potassium carbonate (1.60 g, 11.58 mmol), water (7 ml) and 1,1'-bis(diphenylphosphino)-ferrocenedichloropalladium(II) (75 mg, 0.1 mmol, 1 mol%). Each vial was stirred for 5 min before it was capped and heated for 33 min at 150°C. After cooling to room temperature the contents were combined and diluted with 160 ml of water. The mixture was brought to pH 5 with acetic acid and stirred for 1 h.The precipitate was collected by filtration and washed 4 times with 40 ml 1% aqueous acetic acid. It was then dried under vacuum for 20 h and used without further purification (7.91 g, 83% yield). 
N-(Isoquinolin-8-ylmethylene)-2-methylpropane-2-sulfinamide
Titantetraethylate (1.887 ml, 9.10 mmol) was added in one portion to isoquinoline-8-carbaldehyde (715 mg, 4.55 mmol) in tetrahydrofuran (THF) (10 ml) at room temperature and under air followed by 2-methylpropane-2-sulfinamide (565 mg, 4.66 mmol). The resulting solution was stirred at 55 °C for 2 hours. The reaction was stopped and left to cool down to room temperature before diluting it with ethyl acetate (50 ml) and pouring it into a mixture of brine (40 ml) and ethyl acetate (50 ml). Celite (two large spatulas) was added and the suspension vigorously stirred for 20 minutes. The reaction mixture was filtered through celite and the celite cake washed with an additional 100 ml of ethyl acetate. The organic phase was separated from the aqueous and washed again with 20 ml of brine. The organic layer was dried over MgSO 4 , filtered and evaporated to the desired product as an orange solid (1.14 g, 96% yield). 
4'-Formyl-3-methoxybiphenyl-4-carboxylic acid
Two microwave vials were each loaded with 1.125 g (7.5 mmol) of 4-formylphenylboronic acid, 1.74 g (7.5 mmol) of 4-bromo-2-methoxybenzoic acid, 7 ml of ethanol, 1.14 g (8.25 mmol) of K 2 CO 3 , 6 ml of water and 86 mg (0.075 mmol, 1 mol%) of tetrakis(triphenylphosphine)palladium(0). Each was stirred for 5 min before it was capped and heated for 33 min at 150°C. The reaction mixtures were combined, a black precipitate was removed by filtration, and the volume was reduced to about one half under vacuum.
Water was added until a turbidity remained (total volume about 40 ml) and the mixture was acidified with 2 ml of acetic acid. After stirring for 1 h at rt the colourless precipiate was collected by filtration, thoroughly washed with 1% acetic acid, and dried under vacuum. 97.4 ee). 
Repeated dosing in ob/ob mice
Male ob/ob mice on a C57BlJ/6 genetical background (8 week old, B6.V-Lepob/OlaHsd, Harlan Netherlands) fed ad libitum a standard high carbohydrate (chow) diet (R3, Lantmännen, Sweden), were treated with vehicle (0.5 % hydroxypropyl methylcellulose (HPMC) with equimolar amounts of HCl) or compound 3 (300 µmol/kg b.i.d.) for 1 week.
Body weight was recorded at the start of the study and in the morning of the final day. Rough estimates of cumulative food intake for each cage of mice were made from the difference between weighing food into and remaining in the cages. On the final day, mice were dosed and then fasted for 3 h before blood sampling following 80% CO 2 and 20% O 2 anaesthesia.
Plasma was prepared by centrifugation (12 000g for 2 min at 4°C) and frozen at -20°C.
In vivo phenotypic screening
Open field locomotor activity was assessed over 60 min on two consecutive days in specially designed boxes (Kungsbacka mät och regler teknik, Kungsbacka, Sweden) and an elevated zero maze system (Accuscan Instruments Inc., Columbus, OH) was used to assess anxiety related behavior. Grip strength was assessed using a grip strength meter (Columbus Instruments, Columbus, USA) and assessment of sensory pain (tail flick), acoustic startle and balance was performed as previously described (Gerdin et al., 2006) . Body length (nose to base of the tail) was assessed at 4, 17 and 30 weeks of age. Assessment of indirect calorimetry, water consumption and locomotor activity was performed on animals at 15-16 weeks of age (8 weeks after HFD introduction) in a CLAMS system (Columbus Instruments, Columbus, USA) at thermoneutral temperature (set for wild-type mice at 29.5 o C) as previously described (Gerdin et al., 2006) . The mice were placed in the CLAMS calorimeter chambers with free access to food and water for 72 h. Energy intake was analyzed over 48 h in food deprived mice (12 h) at 18-19 weeks of age as previously described (Bjursell et al., 2006 ) with a minor modification: no initial incubation (80 o C for 1 hour) of the cages was done.
Total faeces produced over the measurement periods were collected and the energy content of the faeces was determined with a bomb calorimeter (C 5000, IKA ® Werke GmbH & Co.
KG, Germany). Rectal core body temperatures were recorded in conscious nonanaesthetized mice during day time (10.00 -11.00 am) using a rectal probe and body composition was assessed by dual energy X-ray absorptiometry (DEXA, GE Lunar, Madison, USA) in Isoflurane anaesthetized mice at 17 weeks of age and then again at 30 weeks of age as previously described (Gerdin et al., 2006) . Oral glucose tolerant test (OGTT) was performed on 19-20 weeks old mice (12 weeks after HFD introduction) as described previously (Bjursell et al., 2007) .
